Compare GSL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | COLL |
|---|---|---|
| Founded | 2007 | 2002 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2008 | 2015 |
| Metric | GSL | COLL |
|---|---|---|
| Price | $44.48 | $24.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $44.00 | ★ $51.40 |
| AVG Volume (30 Days) | 363.5K | ★ 832.2K |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $27.28 | $24.47 |
| 52 Week High | $45.45 | $50.79 |
| Indicator | GSL | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 59.19 | 24.40 |
| Support Level | $37.00 | N/A |
| Resistance Level | $45.07 | $35.89 |
| Average True Range (ATR) | 0.98 | 1.18 |
| MACD | 0.05 | -0.18 |
| Stochastic Oscillator | 75.63 | 0.36 |
Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.